Beta-carotene, vitamin A, and vitamin E associated with increased risk of death
In a systematic review and meta-analysis, the use of beta-carotene, vitamin A, and vitamin E, either alone or combined, was associated with an increased risk of all-cause mortality.
In a systematic review and meta-analysis published in the Journal of the American Medical Association (JAMA), the use of beta-carotene, vitamin A, and vitamin E, either alone or combined, was associated with an increased risk of all-cause mortality.
The authors stated that many people take antioxidant supplements in an effort to improve their health, but that there are no scientific data to determine the effects of the supplements.
This study involved 232,606 participants included in 68 randomized trials that compared various antioxidant supplements either alone or in combination (beta-carotene [n=25], vitamin A [n=16], vitamin C [n=34], vitamin E [n=55], and selenium [n=21]) with placebo or no therapy. Data were selected from a search of The Cochrane Library, MEDLINE, EMBASE, and the Science Citation Index Expanded. The primary objective of the analysis was to determine the effect of antioxidant supplements on all-cause mortality.
The authors stated that further research into the effects of antioxidant supplements is needed, especially to determine the effects of selenium and vitamin C.
SOURCE Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-analysis. JAMA. 2007;297:842–857.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
